Sophiris Bio Culture Company

Mr. Peter T. Slover, CPA has been the Chief Financial Officer of Sophiris Bio, Inc. since January 10, 2013. Mr. Slover served as the Head of Finance and Principal Accounting Officer at Sophiris Bio, Inc. from April 4, 2012 to January 2013. He joined Sophiris in April 2011. He served as the Principal Financial Officer, Principal Accounting Officer and Vice President of Finance and Operations at Anadys Pharmaceuticals Inc. since September 2009. Mr. Slover served as Senior Director of Finance and Controller of Anadys Pharmaceuticals Inc. from January 2009 to September 2009. He joined Anadys Pharmaceuticals Inc. in April 2004. He served as Anadys Pharmaceuticals Inc.'s Manager of Financial Reporting from April 2004 to December 2005, as its Senior Manager, Financial Reporting & Internal Controls from January 2006 to July 2006, as its Associate Controller from August 2006 to December 2006 and as its Controller from January 2007 to December 2008. Prior to joining Anadys Pharmaceuticals Inc., he began his career as an auditor at KPMG LLP where he spent seven years in public accounting. He is a licensed Certified Public Accountant in the State of California. Mr. Slover holds a BS degree in Business Administration from Shippensburg University.

Dr. Allison J. Hulme, Ph.D., has been Chief Operating Officer and Head of Research & Development at Sophiris Bio, Inc. Formerly known as Protox Therapeutics Inc. since April 18, 2011. Dr. Hulme is a highly accomplished pharmaceutical executive. She has over 20 years pharmaceutical drug development experience spanning both large pharmaceutical and mid-sized biotechnology companies. She has a proven track record in all phases of global clinical drug development. She served as an Executive Vice President of Autoimmune, Tysabri, Global Development of Elan Corporation, plc (also known as Elan Pharmaceuticals) since January 2005 and served as its Head of Autoimmune and Tysabri Franchise. Dr. Hulme led the clinical development, commercialization and safety evaluation of Tysabri, obtaining regulatory approval for Tysabri in Multiple Sclerosis in the U.S. and Europe; and for Tysabri in Crohns Disease in the U.S. She served as Executive Vice President, Therapeutic Franchise Group of Elan Corporation, plc since January 2005 and its Executive Vice President for Global Antegren Business. She also served as Executive Vice President of Tysabri Business Enterprise and Senior Vice President & Head of Global Development of Elan Corp. Dr. Hulme joined Elan Corp. Plc. in October 1995. She serves as a Member of Scientific Advisory Board at Io Therapeutics, Inc. She has been Director of InteKrin Therapeutics, Inc. since 2013 and Sophiris Bio, Inc. since October 12, 2016. She has achieved multiple regulatory approvals in the United States and Europe, coupled with hands on global commercial launch experience for the blockbuster drug Tysabri. She held several positions in Clinical Research at Glaxo Wellcome Pharmaceuticals (United Kingdom) and served as Lecturer at Luton University. Dr. Hulme holds an Honors Degree in Science from Luton University and holds her PhD from the Cranfield Institute of Technology.

Dr. Samuel R. Denmeade, also known as Sam, M.D. is a Co-Founder of Inspyr Therapeutics, Inc. and serves as its Chief Clinical Advisor. Dr. Denmeade has been the Chief Scientific Officer of Sophiris Bio Inc. (formerly known as Protox Therapeutics Inc) since October 22, 2007. He has been Scientific Advisor of Medicenna Therapeutics Corp. since July 2017. He served as Chief Scientific Officer at Medicenna Therapeutics Corp. (also known as Medicenna Therapeutics, Inc.) until July 17, 2017. He serves as a Co-Director of the Prostate Cancer Program at the Johns Hopkin Sidney Kimmel Comprehensive Cancer Center. Dr. Denmeade served as the Chief Medical Advisor at Inspyr. He serves as a Member of Scientific Advisory Board of Inspyr and Sophiris Bio Inc. Dr. Denmeade is a Member of the Editorial Board of the journal, The Prostate. He is a Member of the Chemical Therapeutics Program within the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is an Associate Professor of Oncology of Johns Hopkins University School of Medicine. Dr. Denmeade is the Principal Investigator for several clinical trials involving prostate cancer. He is a Co-Inventor of PRX302, Protox's lead candidate for the treatment of prostate cancer and BPH. He has developed several prodrug therapies that are activated by prostate cancer specific proteases and has published over 50 papers in this area. He has an active clinical practice in genitourinary oncology. He has been the recipient of several research awards including those from the NIH, the Department of Defense, the Prostate Cancer Foundation and the Susan Komen Breast Cancer Research Foundation. Dr. Denmeade is a Board Certified Medical Oncologist. Dr. Denmeade graduated magna cum laude with a degree in Biochemistry from Columbia University and earned his MD at Columbia University College of Physicians and Surgeons. He received his residency training at the University of Chicago before his Fellowship Training in Medical Oncology at Johns Hopkins.